since employed by him at Taplow used calf thyroid substrate. Other methods, for instance using rat liver imprints, may show a sizeable incidence of positive individuals even in population controls.
Lupoid-like Syndromes I will briefly deal with two of these (omitting discoid lupus) and mention our experience of rheumatoid-like arthritis and SLE.
Drug-induced SLE-like syndromes appear in association with a mere handful out of the thousands of drugs used; only in a very small proportion of the people who take these do they cause the production of antinuclear factor with or without certain clinical manifestations of this protean disease. In some instances we may be dealing with unrecognized genuine lupus patients who by chance have been given one of these drugs, but in general most patients on such drugs who develop antinuclear factor have few other manifestations of SLE and when the drug is discontinued these manifestations and the antinuclear factor disappear. Lupoid hepatitis: Most people are now beginning to feel that this is essentially hepatitis with abnormal serological reactions rather than systemic lupus with hepatitis and the prognosis is that of the hepatitis rather than determined by any of the lupoid manifestations. Some help with this group may be given by the demonstration of smooth muscle antibody described recently by my colleagues at Taplow (Johnson et al. 1965) and confirmed elsewhere. Antibody to bile canaliculi and to certain glomerular components are often associated. As Johnson et al. (1966) have shown, if patients with hepatitis are divided into those with probable lupoid hepatitis, possible lupoid hepatitis and those without, there is close correlation with this smooth muscle factor. This antibody was not found in cases of systemic lupus erythematosus or in the small series of controls using the calf thyroid method. This serum factor may prove to be ofconsiderable use in the detection and definition of lupoid hepatitis. Rheumatoid-like syndrome associated with SLE: While classical and definite rheumatoid arthritis patients show antinuclear factor in 22% of cases (Ward et al. 1964 ), this does not seem to be particularly associated with systemic disease or more serious outcome, which is that of rheumatoid arthritis''and not of SLE. Cases of SLE, however, sometimes present with or develop rheumatoid-like features. Usually these are mild and transient without erosions. Any rheumatoidlike arthritis which remainsfree of erosions 'for two years or more should7be regarded as doubtful and more likely not to be rheumatoid arthritis.
Occasionally, however, in bona fide SLE, chronic changes ensue, as illustrated by a patient showing the development of ulnar deviation, associated, like ulnar deviation in Jaccoud's syndrome, with hook erosions and subluxation; at post-mortem there was certainly some synovitis and cartilage erosion but histologically this was unlike that seen in typical rheumatoid disease even on steroid medication. The typical synovitis as seen in presteroid days was a benign mild lesion with few infiltrating cells and a surface layer of fibrin. My feeling is that such patients do not have rheumatoid arthritis, but may develop a chronic type of fibrosing synovitis leading to a condition somewhat like that of Jaccoud's syndrome, following repeated attacks of rheumatic fever (Bywaters 1950) , but in this case stemming from lupus synovitis. This does not seem to be adequately recognized. It is another example of the close similarities between these diseases of connective tissue and the necessity for agreed criteria.
In summary, I have tried to stress the importance of agreed and validated criteria in the definition of this group of diseases, which will help both with comparisons.between centres and in defining serological and other manifestations. Systemic lupus erythematosus is a disease remarkable for the variety of serological abnormalities with which it is associated. Of these the most constant and perhaps the most characteristic are the autoantibodies found reacting with cell nuclei. Experimental interest in these serological abnormalitiesand in the antinuclear antibodies as a typical case in pointcentres on two main questions: (1) What is their origin? (2) What relevance, if any, do they have to the pathogenesis of the disease?
With regard to the first question one may be fairly confident that antinuclear antibodies arise as a result of antigenic stimulation. Their great diversityantibodies to large numbers of nuclear determinants being commonly found in lupus serais hardly compatible with their origin in any random process, such as somatic mutation producing clones of cells which spontaneously form autoantibodies.
If these autoantibodies are piroduced in response to antigenic stimulation, what is the source of these antigens? Are they exogenous, such as bacterial or viral nucleoproteins, or endogenous, derived from the patient's own cell nuclei, or both? Although there is no certain information on this point, there is much inferential evidence that endogenous antigens can give rise to antinuclear antibodies. A recent study by C E Biro (1966, personal communication) is relevant. He studied antinuclear antibodies by complement fixation in patients with tissue damage of various kinds. His largest group comprised 40 patients with recent pulmonary infarcts. About three-quarters of these had titres of antinuclear antibody up to 1/128 on the tenth day after the infarct. In several cases preinfarction sera were available and were negative. After four weeks the majority of patients had lost their antinuclear antibodies. These results strongly support the thesis that endogenous antigens arising from tissue damage can give rise to antinuclear antibodies. They also show that the presence of the antibodies does not necessarily provoke an allergic disease and that 'normal' antibody response to the tissue damage is evanescent. The peculiarity in patients with SLE might lie not so much in the fact that they can make autoantibodies but that they do so persistently.
In so far as a possible pathogenetic role of antinuclear antibodies is concerned, the mechanisms by which allergic reactions in general may damage host tissue have been classified into four types by Coombs & Gell (1963) and arguments have been put forward elsewhere (Lachmann 1967 ) that if the autoantibodies in diseases like SLE play a pathogenetic role they are likely to do so by the type 3 reaction which is mediated by soluble antigen-antibody complexes and of which the Arthus reaction is the classical example. By this mechanism a vicious circle could be set up, the allergic inflammation produced by the complexes giving rise to the release of more antigens leading in turn to more antibody formation, more complexes and more allergic inflammation.
Evidence for such a scheme is in large part circumstantial (see Lachmann 1967) but recent work by Tan et al. (1966) provides some direct evidence of circulating antigen-antibody complexes in SLE. These workers were able to demonstrate free DNA in the sera of patients with SLE, and were able to show in one patient, who had anti-DNA antibody, that relapse was accompanied by disappearance of the antibody and appearance of free DNA in the serum.
If indeed type 3 allergic reactions play a part in SLE this knowledge may eventually have important implications. Besides the antigenantibody complexes themselves, two other reactants, complement and polymorphonuclear leucocytes, are essential for this type of reaction. Interference with serum complement is now being attempted in animals using a purified factor from cobra venom to destroy C'3 (Muller-Eberhard et al. 1966) . The role of polymorphs has been analysed by Cochrane & Aikin (1966) who have found in a model system that the damage is due to catheptic enzymes. These enzymes are inactive at neutral pH and this fact points to an important pathogenetic role for the fall in pH caused by glycolysis at the inflammatory site. This could eventually be of some therapeutic significance.
